GW
FHTX icon

GW & Wade’s Foghorn Therapeutics FHTX Stock Holding History

GW & Wade’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-107,770
Closed -$539K – 428
2023
Q3 		$539K Hold
107,770
– – 0.02% 265
2023
Q2 		$759K Buy
+107,770
New +$754K 0.03% 238
2023
Q1 		– Sell
-107,770
Closed -$688K – 386
2022
Q4 		$688K Buy
+107,770
New +$813K 0.03% 225

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GW & Wade's FHTX Position: Q4 2023 in Review

GW & Wade sold out of Foghorn Therapeutics (FHTX) in Q4 2023, closing a stake of 107,770 shares — an estimated $539K sold.

GW & Wade first reported a position in FHTX in Q4 2022 and held it in 3 quarters. The position peaked at $759K in Q2 2023. 59 funds tracked by Wall St. Rank hold FHTX as of Q4 2023.

  • GW & Wade reported no remaining Foghorn Therapeutics position as of Q4 2023 after selling out during the quarter.
  • GW & Wade sold 107,770 Foghorn Therapeutics shares in Q4 2023, an estimated $539K.
  • GW & Wade first reported a position in Foghorn Therapeutics in Q4 2022 and held it in 3 quarters.
  • GW & Wade's Foghorn Therapeutics position peaked at $759K in Q2 2023.
  • 59 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2023.

Based on GW & Wade's 13F filing for Q4 2023, filed 8 Feb 2024.